



Psychiatric Research Report

2004 Award for Research in Psychiatry

On Tuesday morning, May 4, Jack D. Barchas, M.D., will deliver the 2004 APA Award for Research in Psychiatry Lecture, "Adventures in Psychiatric Research: From Neurobiology to Public Policy."

The *Adventures* capture Barchas' broad-based career as a researcher, an educator, institution builder, and as a craftsman of biomedical science policy. The integration of his leadership skills in these areas has, in the three decades that span this career – so far – transformed our understanding of the neurobiological basis of behavior and changed the institutional face of psychiatric research.

The Research

Barchas' research career has been driven by a passion to explore and define the reciprocal relationship between neurobiology and behavior, with an emphasis on emotional behavior. He has pursued the mechanisms and processes underlying this interdependence at every level of investigation – from basic genetic and molecular studies to investigations of how entire neuronal systems are differentially impacted by environmental and pharmacological influences.

"To understand the sequential processes that control neuroregulator systems was of the highest priority," he reminisces. For each neuroregulator system studied, Barchas elaborated neurotransmitter formation, localization, utilization, and inactivation; he performed the first genetic studies of these processes, developed new assays that allowed analyses of smaller brain areas, and identified previously unrecognized neurotransmitters.

A central theme of the Barchas lab focused on the biology of stress responsiveness. His lab was the first to show that neurotransmitters are differently altered by stress. He was also the first to elaborate stress effects on endogenous morphine-like substances, endorphins, leading to his conceptualization and demonstration of Stress-Induced Analgesia, the process whereby stress produces profound inhibition of pain responsiveness.

Each step in the progression of his investigations consistently seeks to demonstrate the essential linkages between neurochemical modulation, changes in emotional and sensory responsiveness, and the related clinical implications. The pivotal question always remains: "How do these neuroregulators control behavior and how are they in turn altered by it?" As such the work continues to occupy a unique place in psychiatry's quest for answers to the most difficult questions in medicine, questions about the biological bases of our emotions and our cognitions, and about the pain and suffering that ensue when they become disturbed.

As Mentor: A Generosity of Spirit

As a mentor, Barchas is renowned for his "light touch," whether the trainee is a beginning medical student, a research fellow, assistant professor, or, as is the case now at Cornell, a senior faculty member. He listens, encourages, facilitates, and reassures, even in the face of initial failures. Far from being extra pairs of hands in the laboratory, trainees are encouraged to appreciate their own unique talents and to hone their skills in pursuit of independent careers. Bowing to the central role of mentorship in the long-term evolution of science, Barchas easily yields credit, even ceding projects when trainees leave to launch their own laboratories. In the words of one former trainee, "Those who know Jack Barchas realize that his greatest professional joy has come from facilitating the development of others."



Jack D. Barchas, M.D.

Institution Building

Barchas has been involved in major institution building at three prestigious universities.

At Stanford (1966-1990) he founded and directed the Laboratory of Behavioral Neuroscience, which in 1976 became the Nancy Pritzker Laboratory of Behavioral Neurochemistry in the School of Medicine. The laboratory gained a reputation as the foremost U.S. center for training in fundamental research related to psychiatry. Indeed, as Associate Chair of the Department of Psychiatry and Behavioral Sciences at Stanford, Barchas established the first residency program in the country designed to provide training opportunities for residents interested in psychiatry research.

The Pritzker lab was unusual in both the depth and breadth of areas it encompassed. Strong efforts were fostered in basic

(continued on next page)

Research Agenda at the Annual Meeting

.....begins on page 5

biochemistry, molecular neurobiology, biochemical neuroanatomy, analytical neurochemistry, behavioral neurobiology, and clinical pharmacology. At the same time, Barchas pursued cooperative interactions beyond his laboratory, developing a rich network of collaborations throughout the medical school and the University. He even reached out to multiple non-medical departments in the University establishing working relationships that ranged from sociology to electrical engineering. Trainees thus had the opportunity to achieve depth of knowledge in a specific disciplinary area while working within a totally integrated setting of interdisciplinary research.

During his tenure at UCLA (1990-1993), as Dean for Research Development and Neuroscience, Barchas continued his efforts in support of major interdisciplinary research activities, establishing endowments and gaining approval for a new neuroscience facility designed to significantly benefit psychiatry research.

Moving to Cornell in 1993, Barchas continues to develop research education programs that now focus upon faculty development. Significantly, these efforts are not directed just toward new faculty but are aimed at facilitating first-time research applications by senior faculty members as well.

Barchas is now Professor and Chairman of the Department of Psychiatry at the Weill-Cornell University Medical College and Psychiatrist-in-Chief at The Weill-Cornell Medical Center of the New York Presbyterian Hospital. He is also Chair of the Board of Trustees, New York Academy of Medicine.

Building Networks

Barchas' efforts to develop research environments continue to encompass an ever wider range of projects and people. As head of the MacArthur Foundation Network on the Psychobiology of Depression, he developed collaborations linking researchers from diverse disciplines and research institutions in efforts at conceptual and methodological cross-fertilization. As current Executive Director of the Pritzker Network on Depression Research, he leads a consortium of scientists from psychiatry departments at Stanford, Cornell, and the University of Michigan in more than a dozen cooperative projects designed to integrate the strengths of each institution in a unified assault on the causes and treatment of major depressive illness.

At the National Level

Barchas' leadership has also extended to the national level where he has fused his creativity as a researcher and an educator into a new role as architect and arbiter of biomedical science policy.

Beginning in the early 1980's and extending into the mid 1990's, Barchas devoted a major portion of his professional life to the work of the Institute of Medicine (IOM), an arm of the National Academies of Science. Under his leadership as chair, the IOM Board on Biobehavioral Sciences and Mental Disorders expanded its role by proactively initiating studies on controversial policy issues, in contrast to its traditional function of responding to legislative and executive evaluation requests. During his tenure as Chair, the Board produced reports that strongly supported basic and clinical research on mental and addictive disorders, and that succeeded in gaining administration backing for research funding in these areas.

(continued on page 4)

J. Christian Gillin, M.D.

The 2004 Award for Research in Psychiatry was awarded jointly to Jack Barchas and to J. Christian Gillin, M.D. Following Dr. Gillin's untimely death in September 2003, at the age of 65, the APA Research Awards Committee, chaired by Alan F. Schatzberg, M.D., voted to proceed with the joint award as a testament not only to Gillin but to the unique contribution that physician researchers can make to the psychiatric profession.

Chris Gillin served as Professor of Psychiatry and Co-Director, Laboratory of Sleep and Chronobiology at the University of California, San Diego, School Of Medicine. Dr. Gillin received a B.A., magna cum laude, from Harvard College and his M.D. from Case Western Reserve School of Medicine. Dr. Gillin first became interested in mental illness, schizophrenia specifically, as a junior high school and high school student, stimulated by his father, an anthropologist, who was himself interested in mental illness across cultures.

Gillin's career-long focus on sleep abnormalities and the fundamental mechanisms of sleep began in his residency at Stanford University and accelerated throughout his tenure at the Intramural Research Program of NIMH. Dr. Gillin's approach used neuropharmacology, sleep, and chronobiology as "neurobiological windows" into the phenomenology, pathophysiology, and treatment of mood disorders, schizophrenia, and alcoholism.

He and his colleagues successfully integrated basic and clinical science approaches in a scientific strategy that he characterized as "bi-directional translational research." He moved comfortably from bench to bedside and back again, often tackling both simultaneously. In his work on depression, for example, he focused on the phenomenology of sleep disturbance in depressed patients while at the same time exploring the basic mechanisms of sleep-wake regulation and circadian mechanisms in both humans and animals.

In 1992, Gillin and colleagues described the first meta-analysis of sleep and psychiatric disorders which firmly established that sleep abnormalities in depression were not diagnostically specific. This review changed the research landscape and the research questions being asked about sleep.

Dr. Gillin's prodigious productivity and far-reaching contributions elevated him, both nationally and internationally, to the highest rank of recognition and respect in the field. He published more than 500 peer-reviewed scientific papers, served on dozens of national advisory boards, prestigious scientific committees, and editorial boards, and was the recipient of numerous honors and awards, including the Society of Biological Society Gold Medal, the Nathaniel Kleitman Distinguished Service Award of the American Academy of Sleep Medicine, the Distinguished Scientist Award of the Sleep Research Society, and the NAMI Exemplary Psychiatrist Award, among others. In 2001, a Festschrift in Gillin's honor resulted in a Special Supplement Issue of the journal *Neuropsychopharmacology*, titled "*Recent Advances in Sleep Chronobiology.*"

Dr. Gillin was a fellow of the American Association for the Advancement of Science and a Distinguished Life Fellow of the American Psychiatric Association. ■

The 2004 Judd Marmor Awardee

David Spiegel, M.D.

David Spiegel, M.D. will receive the 2004 Judd Marmor Award and will deliver the Award Lecture at the APA annual meeting in NYC. Dr. Spiegel is Professor and Associate Chair, Department of Psychiatry and Behavioral Sciences, at Stanford University School of Medicine. He also serves as Director of the Department's Psychosocial Research Laboratory and as Medical Director of the Stanford Hospital Center for Integrative Medicine.

The Judd Marmor Award was established in 1999 through an endowment to the APA by the late Judd Marmor. The annual award is intended to honor "an individual or group in the field of the neuropsychological sciences, as well as in literature, history, or pedagogy, who makes significant contributions to an understanding of the multifactorial, biopsychosocial, elements involved in mental health and illness."

As the fifth recipient of the award,* Dr. Spiegel's body of work defines the concepts embodied in the biopsychosocial model. Since 1976, when he began looking at the effects of support groups for women with metastatic breast cancer, his research and his clinical work have continued to focus on the relationship between psychosocial and biological variables and on the mechanisms through which they might be related. His research has consistently addressed questions aimed at deciphering how the mind affects the body's ability to manage illness.

The Mind – Body Interface

Spiegel's landmark study, "Effect of psychosocial treatment on survival of patients with metastatic breast cancer,"** demonstrated that the application of supportive-expressive group therapy in women with terminal disease not only improved quality of life, having positive effects on mood disturbance, coping and pain management, but also appeared to enhance survival time. Subsequent explorations have identified and elaborated the themes underlying these positive effects: forming strong bonds of mutual support; facing fears of dying and death directly; reordering life priorities; managing relationships with family, friends, physicians.

The benefits of compassionate supportive care for the medically ill, Spiegel asserts, do not indicate that survival is simply mind over matter, but they show that mind *does* matter. Spiegel's current research extends the principles of supportive-expressive psychotherapy to patients with lymphoma, bone marrow transplants, prostate cancer, cardiac arrhythmia, and HIV.

Medical Hypnosis

A long-held interest in hypnosis motivated Spiegel's contributions to the development of medical hypnosis as a treatment for medical symptoms and for treatment side effects. Using PET imaging, and other physiological measurements, he has been able to demonstrate that hypnosis can change the electrical activity and blood flow in those parts of the brain involved in sensory perception. Alterations in perceptions of pain, in turn, can help patients to better manage the pain while even while reducing the dose and the duration of medications. With his father, Herbert Spiegel, M.D., Spiegel produced what for decades has been the classic text on the use of medical hypnosis, *Trance and Treatment: Clinical Uses of Hypnosis*. The volume has been updated and was reissued in April 2004 by the American Psychiatric Press, Inc.



Spiegel continues to apply his ideas on medical hypnosis to research on the use of self-hypnosis with children undergoing painful or embarrassing procedures, to trials of self-hypnosis in facilitating smoking cessation, and to complementary interventions with patients treated for traumatic injury, PTSD, and the dissociative disorders resulting from life-threatening events.

Spiegel collaborated in the work that led to the inclusion of Acute Stress Disorder in *DSM-IV*, and served as editor of an APA publication on dissociative processes, *Dissociation: Culture, Mind and Body* (1994).

Integrated Treatment

In 1998 Dr. Spiegel opened the Center for Integrative Medicine (CIM) at Stanford Medical Center. The Center's evidence-based approach transcends traditional divisions among therapeutic treatments: Eastern, Western, physical, and psychosocial techniques are all used in treatments that include nutrition, exercise, support groups, hypnosis, biofeedback, acupuncture, therapeutic massage, mindfulness meditation and yoga, as well as headache and facial pain management. CIM's programs seek to promote optimal medical care for patients with a range of illnesses and to foster research on techniques designed to help medically ill patients better cope with their illnesses.

Spiegel's current research activities include investigations of: physiological activity underlying altered sensory perception in healthy subjects; impact on cardiovascular illnesses of altered stress hormone (adreno-corticotrophic hormone or ACTH) levels resulting from hypnotic relaxation; interactions and impacts of stress, endocrine function, and social support on differing diseases and health outcomes in aging populations. These projects include multiple collaborative efforts with international investigators from Canada, Norway, Israel, and Australia.


*Previous recipients: Sol Snyder, 2000; Eric Kandel, 2001; Lenore Terr, 2002; Michael Rutter, 2003.

***The Lancet*, October 14, 1989, pp. 888-891.

(continued on next page)

The Lecture

On Tuesday, May 4, from 2 – 3:30 p.m. in Room 1E15 of the Javits Center, Spiegel will deliver the Judd Marmor Award Lecture, “Feeling and Healing: Biopsychosocial Treatments and Their Effects on Medical Illness.” He will review mind-body pathways linking stress and emotion management to diurnal patterns of stress hormones and immune function, and to cancer progression. His talk will elaborate the components of effective biopsychosocial interventions for the medically ill, and he will review ways in which the modulation of perception, emotion, cognition and social support become critical elements in managing medical illness.



Judd Marmor, M.D.

Dr. Judd Marmor, who died in December 2003 at the age of 93, served as President of the APA from 1975 – 1976. He was a prominent educator and psychoanalyst who had a major influence on the field through his public and professional challenge to the designation of homosexuality as a mental illness. Largely through his efforts, the APA Board of Trustees voted to remove homosexuality as a psychiatric disorder from *DSM-II*, 1968. An obituary elaborating Marmor's career and contributions can be found (online) in the February 6, 2004 issue of *Psychiatric News*. <http://pn.psychiatryonline.org/content/vol39/issue3/index.shtml>. ■

2004 Award for Research in Psychiatry

(continued from page 2)

Following these years of service to the National Academies, Barchas became Editor (1994 – 2001) of the *Archives of General Psychiatry*, where he incorporated debates on public policy into a format that continued to define the standard of research excellence for the field of psychiatry.

Service to the APA

In his 35 years as a member of the American Psychiatric Association, Jack Barchas has worked in several capacities to infuse a research perspective onto the Association's agenda. He has served as a member of the Council on Research, including a term as Chair and as Vice-Chair. He also served for five years as Chair of the Distinguished Service Award Committee.

The Award Lecture

At 9:00 a.m. on Tuesday morning, May 4, in Lecture Halls 1E07/8 of the Javits Center, Dr. Barchas will bring to life the activities and roles that have defined his career as a psychiatric researcher and that have positioned him as an eminent recipient of the 2004 APA Award for Research in Psychiatry. ■

Announcements

■ **SPONSOR:** Columbia University

■ **POSITION:** Transcranial Magnetic Stimulation (TMS) Postdoctoral Research Fellowship

DESCRIPTION: Federally funded postdoctoral fellowship available immediately (start date flexible) at the Columbia University Magnetic Brain Stimulation Lab. The fellow will receive extensive hands-on training in transcranial magnetic stimulation (TMS). The lab is equipped with state-of-the-art magnetic stimulators capable of performing single pulse, paired pulse, repetitive stimulation, and magnetic seizure therapy (MST) in humans and in animal models. Access to functional neuroimaging with fMRI and PET is available, as well as access to a full spectrum of clinical psychiatric populations. The fellow may participate in a range of clinical and preclinical studies using TMS as a probe of brain function and as a putative treatment for psychiatric disorders. The initial project will employ TMS in combination with fMRI to study working memory networks affected by sleep deprivation. Technology for simultaneous fMRI and TMS will be developed as part of the project. Clinical training in psychiatry, neurology, or radiology would be desirable.

DEADLINE: Open, ongoing recruitment

CONTACT: Please send CV and list of references to Sarah H. Lisanby, MD, Department of Biological Psychiatry, Columbia University / New York State Psychiatric Institute, 1051 Riverside Drive, Unit 126, New York, NY 10032; 212-543-5568, fax 212-543-6056; e-mail: SHL24@columbia.edu

■ **SPONSOR:** NARSAD

■ **SUBJECT:** 2005 Distinguished Investigator Award

DESCRIPTION: The National Alliance for Research on Schizophrenia and Depression, a private, not-for-profit organization which raises and distributes funds for scientific research into the causes, cures, treatments, and prevention of severe psychiatric brain disorders, announces award opportunities up to \$100,000 for one year to established scientists at the rank of full professor (or equivalent) who maintain a laboratory, to encourage the pursuit of innovative projects in diverse areas of schizophrenia, affective disorders, or other serious mental illnesses.

DEADLINE: Application materials available as of April 1, 2004, at www.narsad.org. First-round applications are due May 14, 2004. Earliest award start date is May 1, 2005.

CONTACT: Research Grants Program (516-829-5576) or grants@narsad.org for more information.



★ **The NIDA Track** Pages 6-7

A special research-based collaboration of
*The National Institute on Drug Abuse and
The American Psychiatric Association*

★ **Special Events in Research** Page 9

★ **New Research Sessions** Page 19

★ **The Forum at Noon** Page 11


★ **Lectures** Page 8

★ **Symposia** Page 10

★ **Scientific & Clinical Reports** Page 12

★ **Courses** Page 16


★ **Workshops** Page 18



Integrating the Science of Addiction Into Psychiatric Practice

The NIDA Track

The National Institute on Drug Abuse (NIDA) and the American Psychiatric Association (APA) present a special research-based program on the concurrence of addiction disorders and mental illness. The impact of comorbidity on both patient and provider is the focus of this special program track at the 2004 APA Annual Meeting. Stress, trauma, obesity, smoking as well as other new and emerging issues in addiction and psychiatry, are built into the series. Each NIDA track session has been approved for category 1 CME credit per session, per session hour.



Monday, May 3, 2004

- *9:00 a.m. - 10:30 a.m. Frontiers in Science Lecture*
Signal Integration in the Brain
Speaker: Paul Greengard, Ph.D.
Javits Center, Level 1, Rooms 1E07/8
- *9:00 a.m. - 10:30 a.m. Issue Workshop*
Drug Abuse and Suicidal Behavior
Javits Center, Level 3, Room 3D02/11
Chair: Eric D. Caine, M.D.
- *9:00 a.m. - 10:30 a.m. Issue Workshop*
**Cocaine and Tobacco Use During Pregnancy:
Adverse Outcomes in Offspring**
Marriott Marquis, Empire/Hudson Rooms
Chair: Vincent L. Smeriglio, Ph.D.
- *11:00 a.m. - 12:30 p.m. Issue Workshop*
**Obtaining Research Funding From NIH:
Keys to Successful Grant Writing**
Marriott Marquis, Empire/Hudson Rooms
Chair: Lucinda Miner, Ph.D.
Speaker: Marina Volkov, Ph.D.
- *2:00 p.m. - 5:00 p.m. Symposium*
Functional Brain Imaging of Addiction
Javits Center, Level 1, Room 1E09
Chair: Elliot A. Stein, Ph.D.
- *2:00 p.m. - 5:00 p.m. Symposium*
**Genetic and Environmental Factors
Contributing to Vulnerability to Addiction**
Marriott Marquis, Cantor/Jolson Rooms
Chair: Jonathan D. Pollock, Ph.D.
- *2:00 p.m. - 5:00 p.m. Symposium*
Obesity: Lessons Learned From Addiction
Marriott Marquis, Empire/Hudson Rooms
Chair: Joseph Frascella, Ph.D.
Discussant: Nora D. Volkow, M.D.
- *2:00 p.m. - 5:00 p.m. Symposium*
Treatment of Chronic Pain in Recovering Addicts
Javits Center, Level 1, Room 1E11
Chair: Jag Khalsa, Ph.D.

The NIDA Track continued

Tuesday, May 4, 2004

- 9:00 a.m. - 10:30 a.m. *Distinguished Psychiatrist Lecture*
Why Does the Human Brain Become Addicted?
Speaker: Nora D. Volkow, M.D.
Director, National Institute on Drug Abuse (NIDA)
Javits Center, Level 1, Room 1E15
- 9:00 a.m. - 11:00 a.m. *Research Advances in Medicine Lecture*
The Epidemiology and Treatment of Psychiatric Comorbidities
Javits Center, Level 1, Room 1E09
Chair: Joel J. Wallack, M.D.
Co-Chair: Geetha Jayaram, M.D.
- 9:00 a.m. - 10:30 a.m. *Issue Workshop*
Addiction Research as a Career Choice in Psychiatry
Marriott Marquis, Herald/Soho Rooms
Chair: Ivan D. Montoya, M.D.
- 9:00 a.m. - 10:30 a.m. *Issue Workshop*
Emerging Pharmacotherapies for the Treatment of Stimulant Dependence
Marriott Marquis, Imperial/Julliard Rooms
Chair: Francis J. Vocci, Ph.D.
- 9:00 a.m. - 10:30 a.m. *Issue Workshop*
Steroid Abuse: Growing Problem for Adolescents and a Hidden Problem for Adults
Marriott Marquis, Alvin/Carnegie Rooms
Chair: Donald R. Vereen, Jr., M.D.
- 11:00 a.m. - 12:30 p.m. *Issue Workshop*
Drugs and Other Addictions: Does One Size Fit All?
Marriott Marquis, Herald/Soho Rooms
Chair: Steven J. Grant, Ph.D.
- 11:00 a.m. - 12:30 p.m. *Issue Workshop*
Stress, Trauma, and Drug Abuse
Marriott Marquis, Marquis Ballroom Salons A/B
Chair: Nancy Pilotte, Ph.D.
- 11:00 a.m. - 12:30 p.m. *Frontiers of Science Lecture*
Anticraving Medication? A New Class of Psychoactive Medication
Speaker: Charles P. O'Brien, M.D.
Javits Center, Level 1, Room 1E15
- 2:00 p.m. - 3:30 p.m. *Frontiers of Science Lecture*
Conceptual and Methodological Flaws in the Evaluation of Addiction Treatment
Speaker: A. Thomas McLellan, Ph.D.
Hilton New York, Trionon Ballroom

- 2:00 p.m. - 5:00 p.m. *Symposium*
Smoking and Comorbid Mental Disorders
Javits Center, Level 3, Rooms 3D06/7
Chair: John R. Hughes, M.D.
- 2:00 p.m. - 5:00 p.m. *Symposium*
ADHD Subtypes and Subgroups at Risk for Substance Use Disorders
Marriott Marquis, Herald/Soho Rooms
Chair: Naimah Z. Weinberg, M.D.

Wednesday, May 5, 2004

- 9:00 a.m. - 10:30 a.m. *Issue Workshop*
Treatment of Patients With Drug Dependence and Psychiatric Illness
Javits Center, Level 1, Room 1E12
Co-Chairs: Wilson Compton III, M.D.
Roger D. Weiss, M.D.
- 11:00 a.m. - 12:30 p.m. *Distinguished Psychiatrist Lecture*
Stress and Relapse to Substance Use Disorder
Speaker: Kathleen T. Brady, M.D.
Javits Center, Level 1, Room 1E07/08
- 2:00 p.m. - 5:00 p.m. *Symposium*
Consequences and Treatment of Marijuana Abuse
Marriott Marquis, Imperial/Julliard Rooms
Chair: Susan R.B. Weiss, Ph.D.
Co-Chair: Jag Khalsa, Ph.D.
- 2:00 p.m. - 5:00 p.m. *Symposium*
Drug Abuse Treatment Issues in Women
Marriott Marquis, Empire/Hudson Rooms
Chair: Cora Lee Wetherington, Ph.D.
Discussant: Kathleen T. Brady, M.D.
- 2:00 p.m. - 5:00 p.m. *Symposium*
Moving the Targets: The Neurobiology of Addiction
Marriott Marquis, Columbia/Duffy Rooms
Chair: Nancy Pilotte, Ph.D.

Thursday, May 6, 2004

- 2:00 p.m. - 5:00 p.m. *Symposium*
Behavioral Treatments for Drug Dependence
Javits Center, Level 1, Room 1E13
Chair: Lisa S. Onken, Ph.D.
Co-Chair: Bruce J. Rounsaville, M.D.

LECTURES

❖ Paul Greengard, Ph.D.

Signal integration in the brain

Frontiers of Science Lecture Series (See also NIDA Track)
Monday, May 3, 9:00 – 10:30 a.m.
Javits Center, Rooms 1E07/08

Slow synaptic transmission mediates the effects of biogenic amine and peptide neurotransmitters through an enormously complicated sequence of biochemical steps involving second messengers, protein kinases, and protein phosphatases. The neurobiology of slow synaptic transmission will provide the basis for presenting recent advances in understanding the mechanisms of action of psychoactive drugs.

❖ Julien Mendlewicz, M.D., Ph.D.

The search for genes of bipolar disorder: From classical genetics to novel molecular targets

International Psychiatrist Lecture Series
Monday, May 3, 11:00 a.m. – 12:30 p.m.
Javits Center, Room 1E15

Classical genetic studies of bipolar illness, modern molecular genetic strategies, and candidate genes of interest for understanding the pathophysiology of bipolar disorder will be reviewed and discussed. Nosological, therapeutic and ethical implications of molecular genetic approaches in psychiatry will be emphasized.

❖ Glen O. Gabbard, M.D.

Mind, brain, and personality disorders

APA Adolf Meyer Award Lecture
Monday, May 3, 11:00 a.m. – 12:30 p.m.
Javits Center, Hall 3E

In psychiatric discourse, the dichotomy of “mind” and “brain” has become a form of code for polarities such as genes vs. environment, medication vs. psychotherapy, and biological vs. psychosocial. Using what we know about personality disorders as well as knowledge gained through recent advances in neuroscience, we can deconstruct these false dichotomies by recognizing psychotherapy as a modality that alters the brain.

❖ Thomas R. Insel, M.D.

Social neuroscience: A new basic science for psychiatry

Frontiers of Science Lecture Series
Monday, May 3, 2:00 – 3:30 p.m.
Javits Center, Rooms

A series of studies has begun to define the neurobiology of social behavior at the molecular, cellular, and systems levels. This presentation will describe several approaches to understanding the neurobiology of social behavior from knockouts of the oxytocin gene in mice to imaging studies in humans.

❖ Jack D. Barchas, M.D.

Adventures in psychiatric research: Neurobiology to public policy

APA Research in Psychiatry Award Lecture
Tuesday, May 4, 9:00 – 10:30 a.m.
Javits Center, Rooms 1E07/08

Dr. Barchas' research career has focused on the reciprocal relationship between neurobiological processes and emotional behavior. He will discuss the trajectory of his career as researcher, educator, and arbiter of biomedical science policy.

❖ Nora D. Volkow, M.D.

Why does the human brain become addicted?

Distinguished Psychiatrist Series (Also see NIDA Track)
Tuesday, May 4, 9:00 – 10:30 a.m.
Javits Center, Room 1E15

Understanding disruptions in the fine balance that normally exists among the brain circuits underlying reward, motivation, memory, and cognitive control has important implications for designing multi-pronged therapies for treating addictive disorders. Strategies for prevention and treatment must integrate approaches that span the molecular to the social.

❖ Charles P. O'Brien, M.D.

Anti-craving medication: A new class of psychoactive medication

Frontiers of Science Lecture Series (See also NIDA Track)
Tuesday, May 4, 11:00 a.m. – 12:30 p.m.
Javits Center, Room 1E15

The latest data from basic neuroscience and clinical research studies show that relapse among treated drug addicts is prevented by medications that reduce drug craving. These data reveal that alterations in the brain continue to produce learned responses to drug-related cues long after detoxification, often resulting in relapse even after successful psychosocial treatment. Now, empirical findings from clinical trials suggest that specific medications for craving-suppression may offer psychiatrists a new class of pharmacological treatment.

❖ David Spiegel, M.D.

Feeling and healing: Biopsychosocial treatments and their effects on mental illness

APA Judd Marmor Award Lecture
Tuesday, May 4, 2:00 – 3:30 p.m.
Javits Center, Room 1E15

The modulation of perception, emotion, cognition and social support are critical elements in managing the stress of medical illness. New mind/body pathways linking stress and emotion management to diurnal patterns of stress hormones, immune function, and to cancer progression will be reviewed.

❖ **A. Thomas McLellan, Ph.D.***Conceptual and methodological flaws in the evaluation of addiction treatment*

Frontiers of Science Lecture Series (See also NIDA Track)
Tuesday, May 4, 2:00 – 3:30 p.m.
Hilton New York, Trianon Ballroom

The lecture will present evidence of a systematic under-estimation of addiction treatment effectiveness due to inappropriate evaluation methods and inappropriate clinical assumptions. Acute care assumptions that govern evaluation methodologies are not consistent with the chronic care assumptions derived from clinical treatment research studies. A more appropriate treatment and evaluation model will be illustrated.

❖ **Joseph T. Coyle, M.D.***The role of glutamate in the pathophysiology of schizophrenia*

Distinguished Psychiatrist Lecture Series
Wednesday, May 5, 9:00 – 10:30 a.m.
Javits Center, Rooms 1E07/08

An aggregate of clinical, post-mortem, and genetic studies suggest that NMDA receptor hypofunction may account for the cognitive impairments, negative symptoms and brain function abnormalities observed in schizophrenia. The NMDA receptor, therefore, presents a novel pharmacologic target for developing more effective treatments.

❖ **Kathleen T. Brady, M.D.***Stress and relapse to substance use disorders*

Distinguished Psychiatrist Series (Also see NIDA Track)
Wednesday, May 5, 11:00 a.m. – 12:30 p.m.
Javits Center, Rooms 1E07/08

Research at the level of biological processes in the brain has identified several neurobiological connections between changes produced by stress and changes produced by both acute and chronic substance use, abuse, and relapse. Further exploration of these connections should lead to pharmacological treatment developments as well as to psychosocial treatment components that emphasize stress management strategies.

❖ **Godfrey D. Pearlson, M.D.***Through the looking glass: Uses of simulation and virtual reality in clinical practice and brain imaging research*

Thursday, May 6, 9:00 – 10:30 a.m.
Javits Center, Rooms 1E07/08

Current achievements, caveats and future prospects of virtual reality-based (VR) applications in psychiatry will be critically reviewed. Clinical VR is used mainly in phobia desensitization. In research settings, VR is used to image simultaneous, complex activation of multiple brain regions that form underlying functional networks of complex cognitive tasks. Novel statistical analysis methods have been designed to accommodate these activities.

Special Events in Research

Advances in Psychopharmacology

❖ *An Update for Clinicians*

Chair: Alan F. Schatzberg, M.D.
Co-Chair: Jeffrey Lieberman, M.D.
Monday, May 3, 2:00 p.m. – 5:30 p.m.
Javits Center
Special Events Hall 1D

Advances in Research

❖ *Frontiers in the Treatment of Psychiatric Disorders*

Chair: Herbert Pardes, M.D.
Co-Chair: Geetha Jayaram, M.D.
Co-Chair: John Greden, M.D.
APA Council on Research and
APA Scientific Program Committee
Monday, May 3, 10:30 a.m. – 12:30 p.m.
Javits Center, Special Events Hall 1D

Research Advances in Medicine

❖ *The Epidemiology and Treatment of Psychiatric Comorbidities*

Chair: Joel Wallack, M.D.
Co-Chair: Geetha Jayaram, M.D.
Collaborative session with NIDA
Tuesday, May 4, 9:00 a.m. – 11:00 a.m.
Javits Center, Room 1E09

Research Consultations

❖ *Evaluating Evidence in Clinical Trials and Research Papers*

Presenter: David Sheehan, M.D.
University of South Florida
Monday, May 3, 11:00 a.m. – 12:30 p.m.
Javits Center, Room 1D03

❖ *Brain Imaging Studies in Schizophrenia*

Presenter: Matcheri Keshavan, M.D.
Western Psychiatric Institute and Clinic
Tuesday, May 4, 11:00 a.m. – 12:30 p.m.
Javits Center, Room 1D03

❖ *Designing and Implementing Studies Contrasting Psychopharmacology and Psychotherapy*

Presenter: Jack Gorman, M.D.
Mount Sinai School of Medicine
Wednesday, May 5, 11:00 a.m. – 12:30 p.m.
Javits Center, Room 1D03

SYMPOSIA

The symposium format at the APA Annual Meeting features a formal three-hour session focused on a specific scientific or clinically relevant topic in psychiatry. There are generally three to five presented papers, a discussant, and a chair or co-chairs. Below are several symposia selected for their relevance to research or to translational issues. **All symposia are held from 2:00 – 5:00 p.m.**; day and location are indicated below.

- ❖ **The Biopsychosocial Model: Myth or Reality?**
 Presidential Symposium
 Monday, May 3
 Javits Center, Room 1E10
 Chair: Pierre Loebel, M.D.
 Co-Chair: Marcia Goin, M.D.
- ❖ **Brain Stimulation: New Treatments for Mood Disorders**
 Monday, May 3
 Javits Center, Rooms 1E01/02
 Chair: John Rush, M.D.
 Co-Chair: Harold Sackeim, Ph.D.
- ❖ **Functional Brain Imaging of Addiction**
 Monday, May 3
 Javits Center, Room 1E09
 Chair: Elliot Stein, Ph.D.
- ❖ **Genetic and Environmental Factors Contributing to Vulnerability to ADD**
 Monday, May 3
 Marriott Marquis, Cantor/Jolson Rooms
 Chair: Jonathan Pollock, Ph.D.
- ❖ **Neurodevelopment and Schizophrenia: Clinical and Basic Science Perspectives**
 Monday, May 3
 Marriot Marquis, Wilder Room
 Chair: Alan Brown, M.D.
- ❖ **Culture, Ethnicity, Race, and Psychopharmacology: New Research Perspectives**
 Tuesday, May 4
 Marriot Marquis, O'Neill Room
 Chair: Pedro Ruiz, M.D.
- ❖ **Delusional Disorder: A Reconsideration of the Scientific and Conceptual Basis for the DSM Reformulation of Paranoia**
 Tuesday, May 4
 Marriot Marquis, Wilder Room
 Chair: Alan Stone, M.D.
 Co-Chair: Robert Cloninger, M.D.
- ❖ **Genetic Correlates in Bipolar Disorders**
 Tuesday, May 4
 Marriott Marquis, Imperial/Julliard Rooms
 Chair: Joseph Goldberg, M.D.
 Co-Chair: Anil Malhotra, M.D.
- ❖ **Interpersonal Psychotherapy: Research Update**
 Tuesday, May 4
 Javits Center, Room 1E12
 Co-Chairs: John Markowitz, M.D.
- ❖ **Neuroimaging Seminar**
 Tuesday, May 4
 Javits Center, Rooms 3D05/8
 Chair: Bruce Cohen, M.D.
- ❖ **Perinatal Depression: Burden, Neurobiology, and Treatment**
 Tuesday, May 4
 Javits Center, Rooms 3D04/9
 Chair: John Greden, M.D.
 Co-Chair: Heather Flynn, Ph.D.
- ❖ **Practice Guidelines, Quality Indicators, and a Practice Research Network: An International View**
 Tuesday, May 4
 Javits Center, Room 1E10
 Chair: John McIntyre, M.D.
 Co-Chair: Wolfgang Gaebel, M.D.
- ❖ **Psychotherapy and Pharmacotherapy: Dissolving the Mind-Brain Barrier**
 Tuesday, May 4
 Javits Center, Room 1E09
 Chair: Barton J. Blinder, M.D.
 Co-Chair: Bernard Beitman, M.D.
- ❖ **The Art and Science of Brief Therapies**
 Tuesday, May 4
 Marriott Marquis, Plymouth/Uris/Shubert Rooms
 Chair: Mantosh Dewan, M.D.
- ❖ **Translational Research on Eating Disorders**
 Tuesday, May 4
 Marriott Marquis, Ziegfeld Room
 Chair: Timothy Walsh, M.D.
 Co-Chair: Michael Devlin, M.D.
- ❖ **Adopting Evidence-Based Practice in the Treatment of Mood Disorders: Canadian Experience**
 Wednesday, May 5
 Marriott Marquis, Ziegfeld Room
 Chair: Sidney Kennedy, M.D.
 Co-Chair: Roumen Milev, M.D.
- ❖ **Anxiety Disorders in Youth: Clinical and Research Updates**
 Wednesday, May 5
 Javits Center, Rooms 3D04/09
 Chair: Marcia Slattery, M.D.
- ❖ **DSM-V Classification of Personality Disorders: The White Paper and Beyond**
 Wednesday, May 5
 Javits Center, Rooms 3D05/8
 Chair: Michael First, M.D.

- ❖ **Moving the Targets: The Neurobiology of Addiction**
Wednesday, May 5
Marriott Marquis, Columbia/Duffy Rooms
Chair: Nancy Pilotte, Ph.D.
- ❖ **Neuroimaging and Emotional Dysregulation in BPD**
Wednesday, May 5
Javits Center, Room 1E14
Chair: Kenneth Silk, M.D.
CoChair: Martin Bohus, M.D.
- ❖ **Neuropsychiatry of Traumatic Brain Injury: Current Research**
Wednesday, May 5
Marriott Marquis, O'Neill Room
Chair: Jonathan Silver, M.D.
- ❖ **Psychiatry, Ethnicity, and Culture: An Update on Ethnopsychopharmacology, Mood, and Anxiety Disorders in Minority Populations**
Wednesday, May 5
Marriott Marquis, Wilder Room
Chair: Shamsah Sonawalla, M.D.
Co-Chair: Rajesh Parikh, M.D.
- ❖ **Psychotic Depression in 2004: The NIMH Collaborative Severe Depression Study**
Wednesday, May 5
Javits Center, Room 1E12
Chair: Barnett Meyers, M.D.
- ❖ **Treatment-Resistant Depression**
Wednesday, May 5
Javits Center, Room 1E10
Chair: Charles Nemeroff, M.D.
- ❖ **From Research to Clinical Practices in Treatment of Patients with BPD**
Thursday, May 6
Javits Center, Room 3D02/11
Chair: John Gunderson, M.D.
- ❖ **How to Practice Evidence-Based Medicine**
Thursday, May 6
Marriott Marquis, Marquis Ballroom Salon C
Chair: Donna Sudak, M.D.
- ❖ **New Clinical Indications for Light Treatment: Status Report**
Thursday, May 6
Javits Center, Rooms 1E01/2
Chair: Raymond Lam, M.D.
- ❖ **Traumatic Stress: The Bridge Between Neuroscience and Psychodynamic Psychiatry**
Thursday, May 6
Marriott Marquis, Plymouth/Uris/Shubert Rooms
Chair: Andrei Novac, M.D.

The FORUM at Noon

A forum is an hour and a half session scheduled over the noon hour. The sessions highlight current issues or events of special interest to psychiatrists. Topics are selected by members of the APA Scientific Program Committee. Each Forum is held from **12 noon until 1:30 p.m.** on the day and place indicated below.

- ❖ **Evidence-Based Psychotherapy**
Chair: Darrel Regier, M.D.
Co-Chair: John McIntyre, M.D.
Monday, May 3, Javits Center, Room 1E10

Leading psychotherapy researchers will provide an overview of empirical evidence for psychotherapies in the treatment of major mental disorders. Presenters will also highlight critical "treatment fidelity" issues affecting the effectiveness of these treatments in routine practice.
- ❖ **ABPN Update: Requirements for ABPN Examination**
Chair: Stephen Scheiber, M.D.
Monday, May 3, Hilton New York, Petit Trianon

Residents and early career psychiatrists are encouraged to attend this overview and active dialogue on issues of certification, recertification and subspecialization.
- ❖ **Ethical Dilemmas in Practice and Research**
Chair: David McDowell, M.D.
Monday, May 3, Javits Center, Room 1E16

The forum will focus on evidence surrounding ethical dilemmas in the treatment of patients with substance abuse.
- ❖ **9/11 Research: A Review and Reviews**
Chair: Anand Pandya, M.D.
Wednesday, May 5, Marriott Marquis, Astor Ballroom

Presenters will review psychological effects of disasters, the time course and treatments of pathological reactions. Major psychiatric findings emanating from 9/11-related research will be discussed and areas for future research identified.
- ❖ **Buprenorphine: What the Clinician Should Know**
Chair: Herbert Kleber, M.D.
Wednesday, May 5, Javits Center, Room 1E10

Discussion will focus on prerequisites of office-based prescribing practices and on the clinically relevant characteristics of the buprenorphine, including including induction and maintenance protocols.
- ❖ **APA and the Pharmaceutical Industry: An Open Forum**
Chair: Stephen Goldfinger, M.D.
Thursday, May 6, Javits Center, Room 1E16

Attention will be focused on some of the more controversial issues surrounding the nature, content, oversight, and potential abuse of industry involvement in research, academic departments, and medical societies.

Scientific and Clinical Report Sessions

Scientific and Clinical Reports are grouped by topic and presented in 90-minute sessions conducted by a chair or co-chair. Within topical sessions, each individual report is followed by 10 minutes of discussion.

Monday, May 3, 11:00 a.m. – 12:30 p.m.

Session 1. Issues in Schizophrenia

Chair: David Garver, M.D., Co-Chair: Jamie Mullen, M.D.
Javits Center, Rooms 1E01/2

2. Rivastigmine and Glantamine Treatment of Schizophrenic Cognitive Impairment *Mohammad Z. Hussain, M.D.*
3. Dosing of Second-Generation Antipsychotics in a Large State Hospital System *Leslie L. Citrome, M.D.*
4. The Meaning of Response in Acute Schizophrenia *Mary Anne Pressman, M.D.*

Session 2. Anxiety Disorders

Chair: Gregory Sullivan, M.D., Co-Chair: Jeffrey Naser, M.D.
Javits Center, Room 1E11

5. Carbon Dioxide Test in Respiratory Panic Disorder: A Clonazepam Trial *Antonio E. Nardi, M.D.*
6. Child Abuse and the Development of PTSD in a Canadian Epidemiological Sample *Michael A. Van Ameringen, M.D.*
7. Tiagabine Treatment of Social Anxiety Disorder *Laszlo A. Papp, M.D.*

Session 3. Spectrum of Personality Disorders

Chair: John Oldham, M.D., Co-Chair: Robert Kelly, M.D.
Javits Center, Room 1E12

8. Childhood Prevalence of BPD *Mary C. Zanarini, Ed.D.*
9. Apparent Versus Reported Sadness: Correlation With Personality Traits *Anand Pandya, M.D.*
10. High-Lethality Suicide Attempts in BPD *Supported by the National Institute of Mental Health; Paul H. Soloff, M.D.*

Session 4. Recovery Issues With Schizophrenia

Chair: Francine Cournos, M.D., Co-Chair: Vital Shah, M.D.
Javits Center, Room 3D03/10

11. Do Patients With Schizophrenia Show Periods of Complete Recovery? A 20-Year Follow-Up *Martin Harrow, Ph.D.*
12. Twenty-Year Outcome in Schizophrenia: What's Sex Got to Do With It? *Linda S. Grossman, Ph.D.*
13. Recovery From Schizophrenic Psychoses Until Age 35 *Erika Lauronen*

Session 5. Complications With Atypical Antipsychotics

Chair: Evaristo Akerele, M.D., Co-Chair: Anton Trinidad, M.D.
Javits Center, Rooms 3D04/9

14. A Program for Treating Weight Gain Induced by Atypical Antipsychotics *Yael Nehama, M.D.*

15. Increased Lipid Levels and Antipsychotic Medication *Hannu J. Koponen, M.D.*
16. QTc Prolongation Associated With Ziprasidone *John W. Goethe, M.D.*

Session 6. Psychotherapy and Psychopharmacology: Dissolving the Mind-Brain Barrier

Chair: David Casey, M.D., Co-Chair: Andrew Skinner
Javits Center, Rooms 3D05/8

17. Interpersonal Psychotherapy for Depressed Elders With Cognitive Dysfunction *Mark D. Miller, M.D.*
18. Integrating Psychotherapy With Medication to Improve Outcome *Ira D. Glick, M.D.*
19. Review of Psychotherapy Research Involving a Pill-Placebo Control *Arthur Rifkin, M.D.*

Session 7. Treatment of Depression

Chair: Thomas Schwartz, M.D., Co-Chair: Marketa Wills, M.D.
Javits Center, Rooms 3D06/7

20. Duloxetine Versus Placebo in the Prevention of Relapse of MDD *Michael J. Detke, M.D.*
21. Response to Antidepressants Is Independent of Gender *Tamar D. Wohlfarth, Ph.D.*
22. Depression and BPD During the Immediate Prepartum Period *Gisele Apter-Danon, M.D.*

Session 8. Health Services

Chair: Mary Jane England, M.D.,
Co-Chair: Steven Epstein, M.D.
Marriott Marquis, Wilder Room

23. Treatment Effectiveness and Functional Recovery in Schizophrenia *Supported by AstraZeneca Pharmaceuticals, Henry A. Nasrallah, M.D.*
24. Ethnic-Matched, Culturally Competent, Model-Based ACT Team: Early Outcome Report *Samuel F. Law, M.D.*
25. Work Disability and Treatment Access in Psychiatry *Farifteh F. Duffy, Ph.D.*

Tuesday, May 4, 11:00 a.m. – 12:30 p.m.

Session 9. Buprenorphine Therapy

Chair: David McDowell, M.D., Co-Chair: Daniel Hicks, M.D.
Javits Center, Rooms 1E01/2

26. Challenges in Increasing Access to Buprenorphine Treatment *Collaborative Session With the National Institute on Drug Abuse Joyce C. West, Ph.D.*
27. A Double-Blind, Double-Dummy, Randomized, Prospective, Efficacy Study of the Partial Mu Opiate Agonist Buprenorphine for Acute Detoxification of Heroin Addicts *Collaborative Session With the National Institute on Drug Abuse Michael R. Oreskovich, M.D.*
28. Buprenorphine: An Effective Treatment for Heroin Addicts *Paolo Marzorati, M.D.*

Session 10. Panic Disorder

Chair: David Casey, M.D., Co-Chair: Andrew Skinner, M.D.
Javits Center, Room 1E11

29. Early Detection of Relapse in Patients with Panic Disorder With Agoraphobia *Supported by the National Institute of Health* *Matig R. Mavissakalian, M.D.*
30. Three-Year Prophylaxis in Panic Disorder: To Continue or Discontinue? *Yujuan Choy, M.D.*
31. Discontinuation of Medications in Panic Patients *Eric D. Peselow, M.D.*

Session 11. Issues in Depression

Chair: Glenn Treisman, M.D.
Co-Chair: Christine Truman, M.D.
Javits Center, Room 1E12

32. Brain Bioenergetics and Thyroid Hormone Treatment in MDD *Dan V. Iosifescu, M.D.*
33. Depressed Outpatients From Primary Care Versus Specialty Care Settings *Bradley N. Gaynes, M.D.*
34. Limits to the Treatment of Major Depression *Gabor I. Keitner, M.D.*

Session 12. ADHD

Chair: Frances Levin, M.D., Co-Chair: Rebecca Brendel, M.D.
Javits Center, Room 3D3/10

35. ADHD Comorbidity in Preschool Children *Atilla Turgay, M.D.*
36. Atomoxetine for Comorbid ADHD and Affective Symptoms *Jeffrey H. Newcorn, M.D.*
37. Abuse Liability Assessment of Atomoxetine in a Drug-Abusing Population *Donald R. Jasinsky, M.D.*

Session 13. Understanding the Effects of Terrorism

Chair: Randall Marshall, M.D., Co-chair: Elspeth Ritchie, M.D.
Javits Center, Rooms 3D04/9

38. Effects of 9/11 and Chronic Stress on Female Drinking and Anxiety *Judith A. Richman, Ph.D.*
39. Psychosocial Predictors of Long-Term Resilience Following the 9/11 Attacks *David Spiegel, M.D.*
40. The Terrorist as a Nonpatient Subject of Psychiatric Investigation *David Rothstein, M.D.*

Session 14. Psychopharmacology

Chair: David Gutman, M.D., Co-Chair: Jeffrey Friend, M.D.
Javits Center, Rooms 3D05/8

41. Antipsychotic Treatment and Sexual Adverse Events: The Role of Prolactin *Rikus Knegtering, M.D.*
42. Three-Bead Extended-Release Carbamazepine Capsule (SPD417) Continuation: Maintenance Therapy in Bipolar Disorder *Terence A. Ketter, M.D.*
43. Parkinsonism in a Nursing Home: Underrecognition *Hubert H. Fernandez, M.D.*

Session 15. Issues in Psychiatric Research and Psychopharmacology

Chair: Nikhil Nihalani, M.D., Co-Chair: Robert Kelly, M.D.
Javits Center, Rooms 3D06/7

44. Concurrent Use of Multiple Antipsychotics in Psychiatric Inpatients *Bonnie L. Szarek, R.N.*
45. How Do Psychiatric Patients Perceive Research Participation? *Cherise Rosen, M.A.*
46. Polypharmacy and Its Ramifications in a Chronic Psychiatric Hospital *Jambur V. Ananth, M.D.*

Session 16. Child and Adolescent Psychiatry

Chair: Cynthia Pfeffer, M.D., Co-Chair: Arun Kunwar, M.D.
Marriott Marquis, Wilder Room

47. Externalizing Behaviors in Preadolescent Children: A National Panel Study *David J. Pevalin, Ph.D.*
48. Gender and the Prediction of Drug and Alcohol Abuse in Adolescent Inpatients *Daniel F. Becker, M.D.*
49. Prevalence and Outcomes of Childhood Adversity in an Australian Population *Stephen J. Rosenman, M.D.*

Session 17. Social and Community Psychiatry


Chair: Susan Stabinsky, M.D., Co-Chair: William James, M.D.
Marriott Marquis, Alvin/Carnegie Rooms

50. Evaluation of an HIV Intervention for Psychiatric Care Providers in South Africa *Pamela Y. Collins, M.D.*
51. Developing Capacity Within CBOS for Health Education and Outreach *Mary Jane Massie, M.D.*
52. Inter-European Countries Comparison on Treatment Use for Mental Health Disorders *Viviane Kovess, M.D.*

Session 18. Violence, Trauma, and Victimization

Chair: Paula Panzer, M.D., Co-Chair: Jason Hershberger, M.D.
Marriott Marquis, Sixth Floor

53. Evaluation of a Therapeutic Interagency Preschool for Traumatized Children *Terrance J. Wade, Ph.D.*
54. Mental Health in Postwar Afghanistan *Barbara Lopes-Cardozo, M.D.*
55. A Three-Dimensional Model of Violence in Schizophrenia *Menahem I. Krakowski, M.D.*



(continued on next page)

Wednesday, May 5, 11:00 a.m. – 12:30 p.m.

Session 19. Alcohol Abuse

Chair: Harvey Stabinsky, M.D., Co-Chair: Robert Kelly, M.D.
Javits Center, Rooms 1E01/2

- 56. The Effects of State Income Inequality and Alcohol Tax on Alcohol Dependence *Claire Henderson, M.D.*
- 57. Effect of Age on Long-Term Outcomes of Inpatient Alcoholism Treatment *Neelofar Khan, M.D.*
- 58. Topiramate Treatment of Alcohol Dependence: Effects on Psychosocial Functioning and Its Relationship With Heavy Drinking *Bankole A. Johnson, M.D.*

Session 20. Cross-Cultural Issues

Chair: Leslie Horton, M.D., Co-Chair: Claudio Cabrejos, M.D.
Javits Center, Room 1E11

- 59. Prevalence of Maternal Depression in Honduras *Lawson R. Wulsin, M.D.*
- 60. Screening for Depression Among Chinese Americans in Primary Care Using Two Items *Albert Yeung, M.D.*
- 61. Suicidal Thinking in Colombian Youth With a History of Attempted Suicide *Ruby C. Castilla-Puentes, M.D.*

Session 21. Suicide

Chair: Douglas Jacobs, M.D., Co-Chair: Robert Davis, M.D.
Javits Center, Room 1E12

- 62. Suicidality and Second-Generation Antipsychotics in Patients With Schizophrenia *Yoram Barak, M.D.*
- 63. Melancholia and Suicide Attempt Probability and Lethality *Michael F. Grunebaum, M.D.*
- 64. Nonviolent Suicides in Women Are Increased During and After High Exposure to Tree Pollen *Teodor T. Postolache, M.D.*

Session 22. Bipolar Disorder

Chair: Robert Post, M.D., Co-Chair: Candace Good, M.D.
Javits Center, Room 3D3/10

- 65. Characteristics of Patients Treated With Gabapentin Referred to a Bipolar Specialty Clinic *Michael J. Ostacher, M.D.*
- 66. Olanzapine/Fluoxetine Combination: Rapid Onset With Low Risk of Mania *Sara A. Corya, M.D.*
- 67. Psychotic Features in MDD Are Associated With Mania *Ekkehard Othmer, M.D.*

Session 23. Biological Psychiatry

Chair: David Casey, M.D.
Co-Chair: Katherine Ruiz-Mellot, M.D.
Javits Center, Rooms 3D04/9

- 68. fMRI of Spatial Working Memory in Schizotypal Personality Disorder *Harold W. Koenigsberg, M.D.*

- 69. Hypofrontality in Patients With Schizophrenia and Bipolar Disorders: An fMRI Study *Mircea C. Polosan, M.D.*
- 70. Low Levels of Antibodies to Cardiolipin in First-Episode and Chronic Schizophrenia *Pinkhas Sirota, M.D.*

Session 24. Psychopharmacology Research in Depression

Chair: Susan Stabinsky, M.D., Co-Chair: Daniel Hicks, M.D.
Javits Center, Rooms 3D05/8

- 71. Prevalence of MTHFR C677T and Methionine Synthase A2756G Polymorphisms in Major Depression and Impact on Response to Fluoxetine Treatment *David Mischoulon, M.D.*
- 72. Oral S-Adenosyl Methionine (SAME) for Antidepressant Augmentation: An Open-Label Trial *Jonathan E. Alpert, M.D.*
- 73. Somatic Symptoms as Predictors of Time to Onset of Response to Fluoxetine in MDD *George I. Papakostas, M.D.*

Session 25. Outcomes in Psychosis

Chair: Carol Trippitelli, M.D., Co-Chair: Mark Rudolph, M.D.
Javits Center, Rooms 3D06/7

- 74. IC-SOHO: Intercontinental Schizophrenia Outpatient Health Outcomes Study *Martin Dossenbach, M.D.*
- 75. Male Patients With Schizophrenia Have Impairment in the Processing of Spatial Information From Dissociated Spatial Reference Frames *Miranda H. Chakos, M.D.*
- 76. Predictors of Outcome in 52 Cases of Psychotic Nonaffective Disorders *Mauricio F. Tohen, M.D.*

Session 26. Substance Abuse

Collaborative Session With the NIDA

Chair: Daniel Chapman, Ph.D., Co-Chair: Vital Shah, M.D.
Marriott Marquis, Wilder Room

- 77. Risk Factors for DSM-IV Cannabis Abuse and Dependence *Jason P. Herrick, B.A.*
- 78. Cannabis Use Reduces the Likelihood of Sustained Remission From Other Drugs *Edward V. Nunes, M.D.*
- 79. Substance-Induced Risk for Depression in a Substance-Dependent Population *Rivka R. Galchen, M.D.*

Session 27. Issues in Psychiatric Epidemiology

Chair: Nikhil Nihalani, M.D., Co-Chair Mark Wright, M.D.
Marriott Marquis, Alvin/Carnegie Rooms

- 80. Ethnicity, Diagnosis, and Health Care Utilization in Incarcerated Women *Catherine F. Lewis, M.D.*
- 81. Psychotropic Drug Utilization in Six European Countries *Giovanni De Girolamo, M.D.*
- 82. Onset of DSM-IV Alcohol Abuse and Dependence: A 10-Year Prospective Study *Deborah S. Hasin, Ph.D.*

Thursday, May 6, 11:00 a.m. – 12:30 p.m.

Session 28. Eating Disorders

Chair: Theodore Weltzin, M.D.
Co-Chair: Andrew Skinner, M.D.
Javits Center, Rooms 1E01/2

83. Weight and Relapse to Cocaine and Alcohol Use in Patients With Eating Disorders Collaborative Session With the National Institute on Drug Abuse; *Olivera J. Bogunovic, M.D.*
84. DSM-IV Comorbidity in Binge-Eating Disorder
Carlos M. Grilo, Ph.D.
85. Males at Risk: Hawaiian and Filipino Adolescents
Alayne Yates, M.D.

Session 29. Addiction Psychiatry

Chair: Lisa Goldfarb, M.D., Co-Chair: Marketa Wills, M.D.
Javits Center, Room 1E12

86. PRISM-IV: Reliable Diagnosis in Alcohol and Drug Abusers Collaborative Session With the National Institute on Drug Abuse; *Sharon Samet, M.S.W.*
87. Cognitive Functioning: Predictors of Outcome in Cocaine-Dependent Patients Collaborative Session With the National Institute on Drug Abuse; *Efrat Aharonovich, Ph.D.*
88. Cocaine Expectancy Questionnaire: Psychometric and Underlying Model Collaborative Session With the National Institute on Drug Abuse; *Marie C. Martin, Ph.D.*

Session 30. Issues in Addictions

Chair: David Casey, M.D., Co-Chair: Jesse Wright, M.D.
Javits Center, Room 3D03/10

89. Psychosocial Therapies for Cocaine Dependence: A Controlled Study Collaborative Session With the National Institute on Drug Abuse; *Adam J. Jaffe, Ph.D.*
90. Patient Treatment Matching With Ambulatory Cocaine Abusers
Charles H. Wilber, M.Ed.
91. Virtual Reality Cue-Reactivity-Controlled Trial for Nicotine Dependence
Patrick S. Bordnick, Ph.D.

Session 31. Sleep and Seasonality

Chair: Karl Doghramji, M.D., Co-Chair: Gerald Donovan, M.D.
Javits Center, Rooms 3D04/9

92. Modafinil Improves Patient Functioning in Shift-Work Sleep Disorder
Milton K. Erman, M.D.
93. Modafinil Treatment of Chronic Shift-Work Sleep Disorder
James K. Walsh, Ph.D.
94. A Comparison of Seasonality of Mood and Behavior in African and African-American Students
Samina M. Yousufi, M.D.

Session 32. Issues in BPD

Chair: Anthony Rothschild, M.D., Co-Chair: John Schwab, M.D.
Javits Center, Rooms 3D06/7

95. The Frequency of DSM-IV Personality Disorders in Psychiatric Outpatients
Mark Zimmerman, M.D.
96. Inhibitory Functioning in BPD: An fMRI Study
Sabine Herpertz
97. Life Changes, Social Adjustment, and Attempted Suicide in BPD and MDD
Thomas M. Kelly, Ph.D.

Session 33. Consultation-Liaison Psychiatry

Chair: Anton Trinidad, M.D., Co-Chair: Sermsak, M.D.
Marriott Marquis, Wilder Room

98. Depression and Nonlinear Heart Rate Dynamics in Older Coronary Patients
Salvador M. Guinjoan, M.D.
99. The Role of Dexmedetomidine in Reducing Delirium in Cardiotomy Patients
Jose R. Maldonado, M.D.
100. Psychiatry Training in Primary Care: Factors for a Satisfactory Program
Hoyle Leigh, M.D.

Session 34. OCD


Chair: Carl Cohen, M.D., Co-Chair: Geoffrey Hopkins, M.D.
Marriott Marquis, Alvin/Carnegie Rooms

101. Self-Administered Versus Therapist-Administered Cognitive-Behavior Therapy for Medication Nonresponders With OCD
David Tolin, Ph.D.
102. Effectiveness of Intensive Residential Treatment of Severe Refractory OCD
S. Evelyn Stewart, M.D.
103. Hyperactive Error Processing in OCD
Nicholas Maltby, Ph.D.

Session 35. Adult ADHD

Chair: Catherine Crone, M.D., Co-Chair: Robert Kelly, M.D.
Marriott Marquis, Sixth Floor

104. Cognitive-Behavioral Therapy for Residual ADHD in Adults
Steven A. Safren, Ph.D.
105. A Controlled Study of Functional Impairments in 500 ADHD Adults
Stephen V. Faraone, Ph.D.
106. Long-Term Safety and Efficacy of Mixed Amphetamine Salts Extended-Release for Adult ADHD
Joseph Biederman, M.D.



Courses p. 16 →

Workshops p. 18 →

COURSES

This year, 100 Continuing Medical Education (CME) Courses will be offered at the Annual Meeting; 27 will be offered for the first time. The courses are either half-day (four hours) or full-day (six hours or eight hours) sessions. Each course meets the requirement for category 1 credit on an hour-for-hour basis. All courses will be held at the Javits Center and Hilton New York. On-site course enrollment is available each day, all day, from Saturday, May 1, through Thursday, May 6, in the Javits Center, North Pavillion, Level 1.

A full description of all 100 courses can be found on the APA Annual Meeting Web site, and will also be included as a separate publication in the annual meeting registration packet. The courses described below focus on topics that emphasize research, new technologies, research applications to clinical practice and related translational themes.

❖ **Course 3: Using Neurofeedback in Your Practice: Introduction With Hands-On Experience**
Co-Directors: Thomas Brod, M.D., Michael Cohen, M.D.

Description: A review of 1) EEG basics, 2) how training impacts both arousal, activation, and inhibition; 3) how the brain learns to change itself; 4) review of the research; 5) how much research supports the role of assessment. Watch or participate in live demonstrations. **Sat., May 1, 8-12; Javits Center**

❖ **Course 5: The Biopsychosocial Formulation: An Approach to Oral Board Presentations**
Co-Directors: William H. Campbell, M.D., Robert M. Rohrbaugh, M.D.

Description: Each of the components (biological, psychological, and social) will be reviewed in a lecture format, and a paradigm will be presented with which to organize historical data. Three videotapes of board-style interviews will be presented and a model board-style biopsychosocial formulation developed. The audience will divide into small groups to develop oral presentations. **Sat., May 1, 9-4; Javits Center**

❖ **Course 8: Behavioral Neuroanatomy: An Introduction**
Director: Nashaat N. Boutros, M.D.

Description: This course is designed to provide an introduction to the anatomy of the human brain for individuals with interest in behavioral disorders. Throughout the course, clinical case vignettes are presented to emphasize a specific anatomical - functional relationship. **Sat., May 1, 1-5; Javits Center**

❖ **Course 9: Psychiatric Genomics: Applications for Clinical Practice**
Director: David A. Mrazek, M.D.

Description: The relevance and utility of genetic testing to optimize outcomes in clinical psychiatric practice will be reviewed. Genes that are involved in the expression of psychiatric illness and specific polymorphisms that have been linked with either diagnosis or treatment response will be highlighted. Clinical issues relevant for genotyping patients to identify their ability to metabolize psychotropic drugs will be reviewed. **Sat., May 1, 1-5; Javits Center**

❖ **Course 20: Advances in Neuropsychiatry**
Director: C. Edward Coffey, M.D.

Description: The major clinical focus of neuropsychiatry is the assessment and treatment of psychiatric or behavioral disorders in patients with brain disorders. The course will explore: recent advances in neuropsychiatry, the neurobiological basis of human behavior, contemporary techniques for imaging structure and function, an update on clinical issues. Participants will be encouraged to present interesting cases from their practices. **Sun., May 2, 9-4; Javits Center**

❖ **Course 21: Evidence-Based Medicine: An Introduction for Psychiatrists**
Director: Gregory E. Gray, M.D.

Description: Participants will learn the five-step, evidence-based medicine process and how to critically appraise clinical trials, review articles, and practice guidelines. **Sun., May 2, 9-4; Javits Center**

❖ **Course 23: Basic Hypnosis: Principles and Applications**
Director: Jose R. Maldonado, M.D.

Description: The course will cover the basics in clinical hypnosis. Several hypnotizability, personality style, and DSM-IV diagnostic categories will be presented as the basis to develop treatment strategies for psychosomatic disorders and psychiatric problems. **Sun., May 2, 9-4; Javits Center**

❖ **Course 24: Melatonin and Light Treatment**
Director: Alfred J. Lewy, M.D.

Description: This course will present the most recent research findings and will enable the practitioner to answer their patients' questions, as well as to advise them appropriately in the use of melatonin and bright light in treating circadian-phase sleep and mood disorders. **Sun., May 2, 1-5; Javits Center**

❖ **Course 31: Improving Your Presentation Skills: A Coaching Approach**

Director: Luis Ramirez, M.D.

Description: The course will rely heavily on role-playing situations with audience participation and discussions geared to improve old presentation skills or develop new ones.

Sun., May 2, 1-5; Javits Center

❖ **COURSE 39: ECT Practice Update**

Director: Charles H. Kellner, M.D.

Description: This course will examine practical topics in patient selection for ECT and ECT techniques. All aspects of the technique, including the most current ECT techniques will be reviewed. Mon., May 3, 8-12; Hilton New York

❖ **Course 44: Advanced Hypnosis: Applications in Psychiatry**

Director: Jose R. Maldonado, M.D.

Description: Attendees are presumed to have minimal formal training in hypnosis. Participants will learn to: assess hypnotizability in the clinical setting; develop psychotherapeutic strategies employing hypnosis; and acquire specific treatment strategies for dealing with anxiety dissociative and somatoforms disorders. Mon., May 3, 9-4; Hilton New York

❖ **Course 51: Temporal Lobe and Limbic System Anatomy: Relation to Psychiatric Illness**

Co-Directors: Andrew L. Lautin, M.D., Jack Davis, M.S.

Description: This basic course will explore distinctive anatomic features exhibited by the limbic domain that endow primacy to this system in the mediation of consciousness and psychiatric illness. Mon., May 3, 1-5; Hilton New York

❖ **Course 53: Doing Research on a Shoestring Budget**

Director: Mantosh J. Dewan, M.D.

Description: This course will benefit junior faculty interested in doing research. Participants will learn how to develop ideas into research projects; develop strategies for supporting projects without grant funding; and get results published.

Tue., May 4, 8-12; Hilton New York

❖ **Course 71: Overview and Update of Sleep Disorders in Medicine**

Director: Karl Doghramji, M.D.

Description: The following will be reviews: entrainment mechanisms governing sleep and wakefulness; the recording of multiple physiological measures during sleep; disorders of sleep. A multimodality approach will be presented, including behavioral, pharmacological, and psychotherapeutic techniques. Tue., May 4, 1-5; Hilton New York

❖ **Course 87: The Neuroendocrinology of Mood Disorders**

Co-Directors: Mark A. Frye, M.D., Natalie L. Rasgon, M.D.

Description: This course will review the three most studied neuroendocrine axes in depression and elaborate potential hormonal treatment options. Wed., May 5, 9-4; Hilton New York

❖ **Course 90: Med-Psych Drug-Drug Interactions**

Co-Directors: Scott C. Armstrong, M.D., Kelly L. Cozza, M.D.

Description: This course will review relevant metabolic pharmacokinetic drug-drug interactions and relevant resources necessary to anticipate drug-drug interactions that may contribute to reduced drug effectiveness and/or side effects. Wed., May 5, 9-4; Hilton New York

❖ **Course 83: Helping Parents From the Inside Out: Attachment, Mindsight, and the Brain**

Director: Daniel J. Siegel, M.D.

Description: Recent advances in a range of scientific fields inform our understanding of the brain and how it shapes and is shaped by interpersonal relationships. This course will offer integrated developmental approaches to enhance children's security of attachment. Wed., May 5, 8-12; Hilton New York

❖ **Course 98: Introduction to Transcranial Magnetic Stimulation (TMS)**

Co-Directors: Ziad H. Nahas, M.D., Leon J. Grunhaus, M.D.

Description: This course will describe the technology of TMS, the basic neurophysiology of stimulation, potential side effects, and applications to neuropsychiatric disorders. Thu., May 6, 8-12; Hilton New York

WORKSHOPS

Two types of workshops are offered at the Annual Meeting. Each is an informal, 90-minute session. Workshops are highly interactive with substantial opportunity for discussion, question and answer periods, and panel interaction.

Component Workshops are proposed by APA committees, councils, task forces, or district branches and address topics relevant to and identified by the components.

- ❖ **Career Choices in Psychiatry: Exploring Fellowship Training**
Monday, May 3, 9:00 a.m. – 10:30 a.m.
Javits Center, Rooms 2D10/11

An opportunity to discuss issues related to career choices, subspecialty training, practice opportunities and professional lifestyles with five panelists who recently completed fellowship training.

- ❖ **Facilitating Research on Minority Populations by Minority Researchers**
Monday, May 3, 9:00 a.m. – 10:30 a.m.
Javits center, Rooms 2D12/13

Learning to recognize appropriate questions and avenues to follow on a minimal budget when conducting research with African American, Hispanic, and American Indian populations.

- ❖ **Novel Careers in Psychiatry: Women Who Have Made Their Own Way**
Monday, May 3, 11:00 a.m. – 12:30 p.m.
Javits Center, Rooms 2D10/11

Personal explorations of non-traditional career paths, the challenges and successful strategies will be discussed.

- ❖ **Update on Practice Guidelines: PTSD and Acute Stress Disorder**
Monday, May 3, 11:00 a.m. – 12:30 p.m.
Javits Center, Rooms 2D12/13

Comments will be solicited on content, implications for the field, and evaluation strategies for the proposed guidelines.

- ❖ **The Neurobiology of Self-Awareness: Learning From Autism and BPD About How We Know Ourselves**
Tuesday, May 4, 9:00 a.m. – 10:30 a.m.
Javits Center, Room 1E11

Recent evidence from animal, neuroanatomical, and scanning studies will be used to consider a variety of pathological mechanisms underlying dysfunctions of self-awareness.

- ❖ **Wherefore Neuroscience: How Much Does the Psychiatrist Need to Know?**
Tuesday, May 4, 11:00 a.m. – 12:30 – p.m.
Javits Center, Rooms 2D10/11

Attention will be directed to the present and potential value of neuroscience in diagnosis and treatment across multiple

classes of psychopathology, and accordingly, to what degree neuroscience should be emphasized in residency training.

- ❖ **Dollars: The Pharmaceutical Industry in Psychiatric Training**
Wednesday, May 5, 9:00 a.m. – 10:30 a.m.
Marriott Marquis, Ziegfeld Room

Psychiatry educators, researchers, and residents will discuss the conflicts of interest and the role of the pharmaceutical industry in funding resident opportunities.

Issue Workshops deal with topics of special interest to psychiatry. Presentations may concern innovative or controversial topics, and may be comprised of multiple, brief presentations or a smaller number of longer presentations.

- ❖ **Psychiatric Research Perspectives in Latin America**
Monday, May 3, 9:00 a.m. – 10:30 a.m.
Marriott Marquis, Cantor/Jolson Rooms

Strategies will be explored for building research bridges between the United States and Latin America.

- ❖ **What Psychiatry Residents Can Expect From NIMH-Sponsored Research Training**
Monday, May 3, 11:00 a.m. – 12:30 p.m.
Marriott Marquis, Booth/Edison Rooms

The full range of NIMH funding mechanisms and incentives for a research-oriented career will be presented.

- ❖ **Obtaining Research funding from NIH: Keys to Successful Grant Writing (NIDA Track)**
Monday, May 3, 11:00 a.m. – 12:30 p.m.
Marriott Marquis, Empire/Hudson Rooms

How to be proactive in the process of applying for NIH funding.

- ❖ **Implementing the Institute of Medicine Report: Fostering Research Careers Via Residencies**
Tuesday, May 4, 9:00 a.m. – 10:30 a.m.
Marriott Marquis, Empire/Hudson Rooms

Representatives of NIMH, RRC, AACAP, and APA will respond to the IOM recommendations.

- ❖ **Addiction Research as a Career Choice in Psychiatry (NIDA Track)**
Tuesday, May 4, 9:00 a.m. – 10:30 a.m.
Marriott Marquis, Herald/Soho Rooms

Psychiatrists at different stages of career development will discuss opportunities and challenges faced by addiction researchers.

❖ **Innovative Methods of Promoting Use of Evidence-Based Psychopharmacology**

Wednesday, May 5, 11:00 a.m. – 12:30 p.m.
Javits Center, Rooms 1E03/4/5

Includes introduction of Web-based interactive, evidence-supported algorithms for psychopharmacological treatments.

❖ **Will Outcomes Evaluation and Research Initiatives Save the Therapeutic Community?**

Wednesday, May 5, 11:00 a.m. – 12:30 p.m.
Javits Center, Rooms 2D10/11

An overview of outcome studies that have established the effectiveness of Therapeutic Communities.

❖ **Evaluating Treatment With Functional Brain Imaging**

Wednesday, May 5, 11:00 a.m. – 12:30 p.m.
Marriott Marquis, Columbia/Duffy Rooms

Using PET and SPECT to predict responses to medication, psychotherapies, and stimulating therapies.

❖ **Ethical and Practical Challenges in Emergency Psychiatric Research**

Wednesday, May 5, 11:00 a.m. – 12:30 p.m.
Marriott Marquis, Gotham Room

Discussion will focus on the need for, barriers to, and guidelines for research in emergency settings.

❖ **The Horns of a Dilemma: Myths & Realities of Drug-Industry Interaction**

Thursday, May 6, 9:00 a.m. – 10:30 a.m.
Javits Center, Rooms 1E03/4/5

A complex of pharmacoeconomic and regulatory issues are inherent in the interplay between industry and physicians.

❖ **Teaching Core Competencies:**

The Challenge for Academic Psychiatry

Thursday, May 6, 9:00 a.m. – 10:30 a.m.
Marriott Marquis, Alvin/Carnegie Rooms

This workshop will focus on the integration of residency educational goals and contemporary hospital teaching practices.

❖ **Evidence-Based Treatment for Schizophrenia in a Correctional Setting**

Thursday, May 6, 11:00 a.m. – 12:30 p.m.
Marriott Marquis, Marquis Ballroom Salon C

The workshop will examine the myths and reality of using treatment algorithms to standardize and improve quality of care in correctional facilities.

New Research Sessions

The New Research program at the annual meeting is designed to provide clinicians access to the most recent research findings on a complete range of topics critical to psychiatric practice. The Young Investigators' sessions were established to encourage medical students, residents, and research fellows to submit their work and to highlight the value of their efforts.

All poster sessions will be in the Galleria on the 4th floor of the Javits Center; Young Investigators' Oral/Slide Sessions will be held in Rooms 3D01/12, 3D03/10, and 3D06/7 in the Javits Center.

❖ **Young Investigators' Poster Session (1)**

Monday, May 3, 9:00 – 10:30 a.m.

❖ **Young Investigators' Oral/Slide Sessions (2-4)**

Monday, May 3, 1:00 – 2:30 p.m.

❖ **Poster Session (5)**

Monday, May 3, 3:00 – 5:00 p.m.

❖ **Poster Session (6)**

Tuesday, May 4, Noon – 2:00 p.m.

❖ **Poster Session (7)**

Tuesday, May 4, 3:00 – 5:00 p.m.

❖ **Poster Session (8)**

Wednesday, May 5, Noon – 2:00 p.m.

❖ **Poster Session (9)**

Wednesday, May 5, 3:00 – 5:00 p.m.

❖ **Poster Session (10)**

Thursday, May 6, Noon – 2:p.m.

Psychiatric Research Report is published by the Division of Research, American Psychiatric Association. We encourage the submission of information items; research training or funding opportunities; announcements of awards and conferences; calls for papers, nominations, etc. Direct all information as well as address changes to: *PRR*, Division of Research, 1000 Wilson Blvd., Suite 1825, Arlington, VA 22209, fax: (703) 907-1087, e-mail: prr@psych.org.

Darrel A. Regier, M.D., M.P.H. Executive Editor
Muriel R. Asher, M.A. Editor
Lizbet Boroughs, M.S.P.H. Legislative Editor
Peggy Shanley-Reichert Copy Editor



Psychiatric Research Report (PRR) MAILING LIST UPDATE

PLEASE RETURN THIS FORM IF YOUR ADDRESS IS INCORRECT ON THE MAILING LABEL BELOW OR IF YOUR ADDRESS WILL SOON CHANGE. **PRINT** YOUR NAME, ADDRESS, PHONE AND E-MAIL ADDRESS IN THE SPACE PROVIDED. YOU MAY FAX YOUR RESPONSE.

Name: _____

Address: _____

E-Mail: _____

Please return this form (including your mailing label) to:

Psychiatric Research Report
Division of Research
American Psychiatric Association
1000 Wilson Boulevard, Suite 1825
Arlington, VA 22209
FAX: 703-907-1087 ■ E-mail: prr@psych.org

**American
Psychiatric
Association**

1000 Wilson Boulevard, Suite 1825
Arlington, VA 22209



Non-Profit Org.
U.S. Postage
PAID
American Psychiatric
Association
